CytoMed Therapeutics Ltd (GDTC) - Dilution Analysis

Visualizing historical and potential share dilution over time

View Stock Details

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Dilution Analysis

Low Risk

Limited dilution potential

Last updated: March 31, 2026

Risk Assessment Details

Potential Dilution: 0.0% of current shares

Recent Dilution: 2.5% (2 years)

Historical Dilution Factor: minimal recent dilution

Outstanding Shares

12M

Potential Supply

Additional shares possible

Splits

None

Past 2 years

Summary

GDTC currently has 11.8M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 2.5% over the past 2 years.

Share Structure Timeline

Outstanding Shares

Total Supply

Historical Data Points

Date	Event	Outstanding
Mar 31, 2026	20-F filing \| 11.8M shares outstanding	12M
Jun 13, 2025	F-3 filing: CytoMed Therapeutics Limited may offer ordinary shares, share purchase contracts, share purchase units, warrants, debt securities, rights or units, up to an aggregate initial offering price of U.S.$50,000,000.	12M
Apr 28, 2025	20-F filing \| 11.5M shares outstanding	12M
Apr 22, 2024	20-F filing \| 11.5M shares outstanding	12M
May 01, 2023	20-F filing \| 11.5M shares outstanding	12M
Nov 18, 2022	F-1 filing: This F-1 filing discusses the proposed IPO of ordinary shares, including shares offered by the company and selling shareholders, with an underwriter's over-allotment option. It mentions the intention to list on the Nasdaq Capital Market under the symbol 'GDTC' and provides details on the use of proceeds, lock-up agreements, and risk factors associated with investing in their ordinary shares.	3.2B

Back to GDTC Details